[
    {
        "trial_id": "NCT04657016",
        "brief_title": "A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program",
        "official_title": "Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)",
        "lillyAlias": [
            "I8F-MC-GPHM"
        ],
        "brief_summary": "This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).",
        "trial_status": "COMPLETED",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Obesity",
            "Overweight"
        ],
        "drugs_list": [
            "Tirzepatide",
            "Placebo"
        ],
        "enrollment": 579,
        "inclusion_criteria": "inclusion criteria: \n\n Have a body mass index (BMI) \u226530 kg/m2 or \u226527 kg/m2 and previously diagnosed with at least 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease\n History of at least one unsuccessful dietary effort to lose body weight",
        "exclusion_criteria": "exclusion criteria: \n\nDiabetes mellitus\nChange in body weight greater than 5 kg within 3 months prior to starting study\nObesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity\nHistory of pancreatitis\nFamily or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\nHistory of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years\nAny lifetime history of a suicide attempt",
        "keywords": [
            "Diet",
            "Exercise",
            "Metabolism and Nutrition Disorder",
            "Behavioral Modification"
        ]
    },
    {
        "trial_id": "NCT00456885",
        "brief_title": "The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women",
        "official_title": "The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus",
        "lillyAlias": [],
        "brief_summary": "This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes.\n\nThe study is 35 weeks long and includes 19 outpatient visits. Participants will receive exenatide for 16 weeks and placebo for 16 weeks with a 3 week rest period in between. Neither participants nor investigators will know whether exenatide or placebo is being administered. Participants will be started randomly on either exenatide or placebo.\n\nOur hypothesis is that treatment with exenatide will curb appetite and lead to weight loss and may lead to changes in energy expenditure.",
        "trial_status": "COMPLETED",
        "phase": [
            "PHASE4"
        ],
        "diseases_list": [
            "Obesity",
            "Impaired Glucose Tolerance"
        ],
        "drugs_list": [
            "exenatide",
            "Placebo"
        ],
        "enrollment": 41,
        "inclusion_criteria": "inclusion criteria: \n\n1. Females aged 25-60\n2. BMI 28-35 kg/m2\n3. No known diagnosis of diabetes\n4. No known diagnosis of coronary heart disease\n5. Self-described sedentary lifestyle with minimal regular cardiovascular exercise (no more than 1 hour per week)\n6. Stable weight (variation \\< 3 kg within 6 months of screening visit)\n7. Ability to give informed consent\n8. Ability to follow verbal and written instructions\n9. Use of medically approved form of contraception (monophasic oral contraception, intra uterine device, surgical sterilization or 2 combined barrier methods)\n10. Nonsmoker (tobacco, marijuana)\n11. Outpatient visits every 2 weeks throughout the study period are required. While most of these visits are short (15 minutes)ability to commute to the performance site in Boston, on a regular basis, is necessary.",
        "exclusion_criteria": "exclusion criteria: \n\n1. Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria\n2. Coronary heart disease (history of myocardial infarction or unstable angina pectoris)\n3. Uncontrolled hypertension hypertension (BP \\> 150/90 mmHg on or off antihypertensive medication)\n4. Uncontrolled dyslipidemia (LDL \\> 200 or TG \\> 400 on or off lipid lowering medication)\n5. Tobacco, marijuana or intravenous drug use\n6. Shift workers (night shift or alternating day/night shifts)\n7. Recent weight loss (\\> 3 kg within 4 months of the screening visit)\n8. Gastroparesis\n9. Inflammatory bowel disease\n10. Malignancy treated with chemotherapy within the past 3 years\n11. History of pancreatitis\n12. Depression requiring hospitalization or diagnosis of psychosis\n13. Renal insufficiency (creatinine clearance \\< 50 ml/min)\n14. Transaminases \\> 2x above the normal range\n15. Pregnancy within 6 months of the screening visit\n16. Breastfeeding\n17. Failure to use medically approved contraceptive methods\n18. History of an eating disorder (anorexia, bulimia or laxative abuse)\n19. History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)\n20. New diagnosis of hypo or hyperthyroidism within 1 year of screening visit\n21. Previous participation in a clinical study with exenatide\n22. Presence or history of allergic reaction to multiple drugs",
        "keywords": [
            "obesity",
            "double blind",
            "placebo controlled",
            "weight loss",
            "appetite",
            "energy expenditure"
        ]
    },
    {
        "trial_id": "NCT04881760",
        "brief_title": "A Study of LY3437943 in Participants Who Have Obesity or Are Overweight",
        "official_title": "A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities",
        "lillyAlias": [
            "J1I-MC-GZBF"
        ],
        "brief_summary": "This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.",
        "trial_status": "COMPLETED",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Obesity",
            "Overweight"
        ],
        "drugs_list": [
            "LY3437943",
            "Placebo"
        ],
        "enrollment": 338,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have a Body Mass Index (BMI) ) \u226530 and \u226450 kilograms per square meter (kg/m\u00b2), or \u226527 kg/m\u00b2 and \\<30 kg/m\u00b2, with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease\n Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have type 1 or type 2 diabetes mellitus\nParticipants must not have had an increase or decrease in body weight \\> more than 5 kg (11 pounds) within the past 3 months\nParticipants must not have had surgery for obesity or plan to have such surgery during the study\nParticipants must not be using medications that promote weight loss or cause weight gain\nParticipants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)\nParticipants must not have used marijuana within the last 3 months.\nParticipants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months\nParticipants must not have active cancer within the last 5 years\nParticipants must not have uncontrolled high blood pressure\nParticipants must not have liver disease other than non-alcoholic fatty liver disease\nParticipants must not have renal impairment with estimated glomerular filtration rate (eGFR) \\<45 mL/min/1.73 m2\nParticipants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection\nParticipants must not have a major problem with depression or other mental illness within the last 2 years\nParticipants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)\nFemale participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)",
        "keywords": [
            "Nutritional or Metabolism Disorder",
            "Weight Loss",
            "Overnutrition",
            "Incretins",
            "Hormones",
            "Physiological Effects of Drugs"
        ]
    },
    {
        "trial_id": "NCT06672549",
        "brief_title": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)",
        "official_title": "A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight",
        "lillyAlias": [
            "J4M-MC-PWMP"
        ],
        "brief_summary": "The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Obesity",
            "Overweight"
        ],
        "drugs_list": [
            "Orforglipron",
            "Placebo"
        ],
        "enrollment": 125,
        "inclusion_criteria": "inclusion criteria: \n\n Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.\n Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart \\[CDC-NCHS, 2022\\]); OR\n Applies to participant age between 12 and \\<18 years old. Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,\n\n   hypertension\n   type 2 diabetes (T2D)\n   prediabetes\n   dyslipidemia\n   obstructive sleep apnea\n   metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)",
        "exclusion_criteria": "exclusion criteria: \n\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band\u00ae gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state.\nHave HbA1c \\>9.0% (75 mmol/mol) as measured by central laboratory at screening.\nHave a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.",
        "keywords": []
    },
    {
        "trial_id": "NCT06009653",
        "brief_title": "Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity",
        "official_title": "Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity",
        "lillyAlias": [],
        "brief_summary": "The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with double blind treatment to evaluate the effects of a drug called tirzepatide in combination with an innovative, culturally-appropriate, intensive lifestyle intervention (ILI) delivered by community health workers (CHWs) in Latino adults with obesity. Participants will be randomized to 1) standard care (SC, n=25); 2) culturally-tailored dietary and behavioral intensive lifestyle intervention (ILI, n=25) provided by CHWs plus placebo; or 3) ILI plus tirzepatide (ILI-TRZ) for 52 weeks to evaluate the intervention's effect on: i) weight loss; ii) clinical efficacy (change in body fat mass, liver fat, intra-abdominal fat mass and intrahepatic triglyceride content, oral glucose tolerance, glycemic control, insulin sensitivity and b-cell function, plasma lipids, blood pressure, sleep duration, quality and behaviors, physical performance scores); iii) adherence and fidelity to the intervention (adherence to the intervention and barriers to long term adherence, quality-of-life, fidelity of the implementation by CHWs, CHW's and study participants' acceptability and satisfaction with the intervention and eating behaviors. Placebo or tirzepatide will be injected subcutaneously in the abdomen or thigh once a week for 12 months.",
        "trial_status": "TERMINATED",
        "phase": [
            "PHASE4"
        ],
        "diseases_list": [
            "Obesity",
            "Metabolic Disease"
        ],
        "drugs_list": [
            "Standard Care",
            "Culturally-tailored dietary and behavioral intensive lifestyle intervention",
            "Placebo",
            "Tirzepatide"
        ],
        "enrollment": 32,
        "inclusion_criteria": "inclusion criteria: \n\n Self-reported Hispanic and/or Latino heritage\n Body Mass Index (BMI) 30-42 kg/m\u00b2\n HbA1c \u2264 6.4%",
        "exclusion_criteria": "exclusion criteria: \n\nPrevious diagnosis of diabetes or fasting glucose \u2265 126 mg/dl or 2 hr oral glucose tolerance test plasma glucose \u2265 200 mg/dl\nUnstable weight (\u22654% during the last 2 months prior to study enrollment)\nCPAP treatment for obstructive sleep apnea\nSevere cardiovascular disease within the 6 months prior to study enrollment\nSevere organ system dysfunction\nKnown clinically significant gastric emptying abnormality\nHistory of chronic or acute pancreatitis\nThyroid-stimulating hormone (TSH) \\>1.5X the upper limit of normal\nMedical conditions that cause obesity\nHistory of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder within the last 2 months\nActive substance abuse with alcohol or drugs\nUncontrolled hypertension\nLiver disease\nCalcitonin level of \u226520 ng/L if eGFR \u226560 mL/min/1.73 m2 or \u226535 ng/L if eGFR \\<60 mL/min/1.73 m2\nFamily or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\nHistory of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years\nSevere anemia\nPregnant or breastfeeding\nMetal implants that preclude MRI testing\nUse of medications that are known to affect the study outcome measures\nDo not agree to use contraception throughout the study period in male and female participants of reproductive and childbearing age\nPersons who are not able to grant voluntary informed consent\nUnable or unwilling to follow the study protocol\nHave any other condition not listed in this section (e.g. hypersensitivity or intolerance) that is a contraindication of GLP-1R agonists",
        "keywords": [
            "Latinos",
            "Obesity",
            "Plant-forward diet",
            "Tirzepatide"
        ]
    },
    {
        "trial_id": "NCT06584916",
        "brief_title": "A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)",
        "official_title": "A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",
        "lillyAlias": [
            "J2A-MC-GZPN"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.",
        "trial_status": "ENROLLING_BY_INVITATION",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Obesity",
            "Overweight"
        ],
        "drugs_list": [
            "Orforglipron",
            "Placebo"
        ],
        "enrollment": 300,
        "inclusion_criteria": "inclusion criteria: \n\n Have completed the SURMOUNT-5 study on study treatment",
        "exclusion_criteria": "exclusion criteria: \n\nHave Type 1 Diabetes, Type 2 Diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma\nHave a prior or planned surgical treatment for obesity\nHave acute or chronic hepatitis\nHave a history of acute or chronic pancreatitis",
        "keywords": [
            "Maintenance",
            "Weight maintenance",
            "Body weight changes",
            "Weight loss",
            "Incretins",
            "Hormones",
            "Hormone substitutes",
            "Hormone antagonists",
            "Physiological effects of drugs"
        ]
    },
    {
        "trial_id": "NCT06672939",
        "brief_title": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities",
        "official_title": "Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral Versus Placebo in Adolescent Participants Who Have Obesity, or Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)",
        "lillyAlias": [
            "J4M-MC-PW01"
        ],
        "brief_summary": "The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Obesity",
            "Overweight"
        ],
        "drugs_list": [
            "Orforglipron",
            "Placebo"
        ],
        "enrollment": 125,
        "inclusion_criteria": "inclusion criteria: \n\nJ4M-MC-PWMP\n\n Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.\n Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart \\[CDC-NCHS, 2022\\]); OR\n Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,\n\n   hypertension\n   type 2 diabetes (T2D)\n   prediabetes\n   dyslipidemia\n   obstructive sleep apnea\n   metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)",
        "exclusion_criteria": "exclusion criteria: \n\nJ4M-MC-PW01\n\nPrepubertal (Tanner stage 1)\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening\n\nJ4M-MC-PWMP\n\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band\u00ae gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state.\nHave HbA1c \\>9.0% (75 mmol/mol) as measured by central laboratory at screening.\nHave a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.",
        "keywords": []
    },
    {
        "trial_id": "NCT05051579",
        "brief_title": "A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities",
        "official_title": "A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities",
        "lillyAlias": [
            "J2A-MC-GZGI"
        ],
        "brief_summary": "The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.",
        "trial_status": "COMPLETED",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Obesity",
            "Overweight and Obesity"
        ],
        "drugs_list": [
            "LY3502970",
            "Placebo"
        ],
        "enrollment": 272,
        "inclusion_criteria": "inclusion criteria: \n\n Have a body mass index (BMI) of \u226530-kilogram square meter (kg/m\u00b2)\n Have a BMI \u226527 kg/m\u00b2 and \\<30 kg/m\u00b2 with at least 1 of the following weight-related comorbidities eg; \\[Have hypertension, or dyslipidemia, cardiovascular disease\\]\n Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)",
        "exclusion_criteria": "exclusion criteria: \n\nHave any prior diagnosis of diabetes\nHave a prior or planned surgical treatment for obesity\nHave obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity\nHave renal impairment measured as estimated glomerular filtration rate (eGFR) \\<30 milliliter (mL)/minute (min)/1.73 m\u00b2\nHave a history of acute chronic pancreatitis\nHave a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.\n\nWithin 3 months prior to screening:\n\nHave poorly controlled hypertension\nHave history of acute myocardial infarction\nHave history of cerebrovascular accident (stroke)\nHad hospitalization due to congestive heart failure (CHF)\nHave cancer\nHave human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening\nHave hepatitis B and/or positive hepatitis B surface antigen",
        "keywords": []
    },
    {
        "trial_id": "NCT05623839",
        "brief_title": "A Study of LY3305677 in Participants With Obesity Or Overweight",
        "official_title": "A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677",
        "lillyAlias": [
            "I8P-MC-OXAG"
        ],
        "brief_summary": "The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.",
        "trial_status": "COMPLETED",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Overweight",
            "Obesity"
        ],
        "drugs_list": [
            "LY3305677",
            "Placebo"
        ],
        "enrollment": 32,
        "inclusion_criteria": "inclusion criteria: \n\n Participants who are overtly healthy as determined by medical evaluation\n Participants with stable weight for 3 months and body mass index of 27.0 and 50.0 kilograms per square meter (kg/m\u00b2)",
        "exclusion_criteria": "exclusion criteria: \n\nHave history of type 1 diabetes mellitus or type 2 diabetes mellitus, ketoacidosis, or hyperosmolar state or coma",
        "keywords": []
    },
    {
        "trial_id": "NCT05548231",
        "brief_title": "A Study of LY3437943 in Chinese Participants With Obesity Or Overweight",
        "official_title": "A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943",
        "lillyAlias": [
            "J1I-MC-GZBE"
        ],
        "brief_summary": "The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.",
        "trial_status": "COMPLETED",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Overweight",
            "Obesity"
        ],
        "drugs_list": [
            "LY3437943",
            "Placebo"
        ],
        "enrollment": 32,
        "inclusion_criteria": "inclusion criteria: \n\nFor All Participants:\n\n Are native Chinese males or females\n Have a body mass index of \u226527 and \u226440 kilograms per square meter (kg/m\u00b2)\n Have not modified diet or adopted any nutritional lifestyle modification for 3 months\n Have stable body weight for the last three months\n Male participants must agree to use contraception during the study and for 4 months afterward and female participants must be woman of nonchildbearing potential\n\nFor Type 2 Diabetes Mellitus (T2DM) Participants:\n\n Have type 2 diabetes for at least 3 months\n Have a glycated hemoglobin (HbA1c) value of \u22657.0% and \u226410.5% and have been treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening",
        "exclusion_criteria": "exclusion criteria: \n\nFor All Participants:\n\nHave an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week and smoke more than 10 cigarettes, or cigarette equivalent (as determined by investigator), per day\nHave other serious or unstable illnesses\nHave had an episode of severe hypoglycemia\nCurrent or chronic history of liver disease.\n\nFor T2DM Participants:\n\nHave type 1 diabetes mellitus\nHave uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization\nAny glucose-lowering medications other than metformin within 3 months prior to screening",
        "keywords": []
    }
]